Multiple Sclerosis Clinical Trial
— MST3KOfficial title:
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Verified date | May 2018 |
Source | Oregon Health and Science University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis
Status | Completed |
Enrollment | 15 |
Est. completion date | January 10, 2017 |
Est. primary completion date | January 10, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Confirmed diagnosis of MS of any type - Age 18 to 50 years - Weight range 45-90 kg (100-200 lbs) - Lesions on brain MRI Exclusion Criteria: - History of hypo or hyperthyroidism and a normal TSH - History of high blood pressure (hypertension) [ - Resting blood pressure greater than 150/95, resting heart rate greater than 100 - History of coronary artery disease or clinically significant arrhythmia, clinically significant abnormalities on EKG - History of diabetes - History of anemia or renal (kidney) disease - Clinically significant abnormalities on metabolic panel or serum hematocrit below 32 % - History of atrophic gastritis - History of anxiety disorder or bipolar disorder - Serious psychiatric or medical conditions that would preclude reliable participation in the study - Use of illicit substances or alcohol abuse - Current use of fingolimod (Gilenya) - Current or prior use of mitoxantrone (Novantrone) - Current use of stimulants (methylphenidate, atomoxetine, dextroamphetamine,phentermine) - Current use of any blood thinners such as warfarin or apixaban (Aspirin is ok) - Medications which would metabolized faster in the presence of thyroid hormone (Insulin, oral hypoglycemic agents and oral anticoagulants) - Severe head tremors (which would impair the ability to perform VEPs) - Present or recent use of medications that could interact with the thyroid hormone (iodine containing agents such as kelp supplements, amiodarone, iodinated contrast given for CT or xray), P450 stimulants (phenytoin, carbamazepine, phenobarbital, and rifampin) - Corrected visual acuity worse than 20/50 in either eye or other eye issues that would prevent reading of a standard eye chart - Head tremors or other tremors that would prevent sitting relatively still for a vision test - Patients taking proton pump inhibitors (PPIs) or H2 blockers will be excluded unless they can safely not take these medications during the week of study drug administration. - Patients taking Ampyra (dalfampridine) will be excluded unless they can safely not take these medications during the week of study drug administration. - Pregnancy, breastfeeding, or intention to become pregnant in the following month - Inability to receive an MRI (e.g. implanted metal device) |
Country | Name | City | State |
---|---|---|---|
United States | Oregon Health and Science University | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS | MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation) | 1 week | |
Secondary | Reliability of Visual Evoked Potential (VEP) Testing (ICC) | P100 latency will be compared before and after treatment with L-T3 in subjects receiving the active treatment to assess reliability of the test for future assessment of treatment effect. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |